Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
By: Tianyu Li, Xiaofang Tang, Ying Song, Yi Yao, Xueyan Zhao, Zhan Gao, Yuejin Yang, Runlin Gao, Bo Xu and Jinqing Yuan
References
- World Health Organization.
Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016 . Geneva: World Health Organization; 2018. - Chen W, Du W, Fan X, et al.
Report on Cardiovascular Diseases in China (2017) . Beijing: National Centre for Cardiovascular Diseases of the People’s Republic of China; 2018. - Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 8 June 2007; 356: 2388–2398. DOI: 10.1056/NEJMsa053935
- Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 3 March 2004; 109: 1101–1107. DOI: 10.1161/01.CIR.0000118498.35499.B2
- Piepoli MF, Corra U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: A policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol. 22 June 2014; 21: 664–681. DOI: 10.1177/2047487312449597
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 26 May 2016; 37: 2315–2381. DOI: 10.1093/eurheartj/ehw106
- Smith SC,
Jr. , Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 5 November 2011; 124: 2458–2473. DOI: 10.1161/CIR.0b013e318235eb4d - Kotseva K, De Bacquer D, Jennings C, et al. Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients with Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Glob Heart. 2017; 12: 315–322 e313. DOI: 10.1016/j.gheart.2015.11.003
- Zhao M, Klipstein-Grobusch K, Wang X, et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995–2015: A systematic review and meta-analysis. PLoS One. 21 April 2017; 12: e0175947. DOI: 10.1371/journal.pone.0175947
- Kumbhani DJ, Fonarow GC, Cannon CP, et al. Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. Am J Med. 2015; 128: 426 e421–429. DOI: 10.1016/j.amjmed.2014.11.013
- Ma TT, Wong ICK, Man KKC, et al. Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis. PLoS One. 19 January 2019; 14: e0210988. DOI: 10.1371/journal.pone.0210988
- Lu J, Zhang L, Lu Y, et al. Secondary prevention of cardiovascular disease in China. Heart. 26 January 2020. DOI: 10.1136/heartjnl-2019-315884
- Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 12 Febuary 2019; 26: 824–835. DOI: 10.1177/2047487318825350
- Redfern J, Hyun K, Chew DP, et al. Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: Results from a large prospective audit in Australia and New Zealand. Heart. 11 June 2014; 100: 1281–1288. DOI: 10.1136/heartjnl-2013-305296
- Webster R, Castellano JM, Onuma OK. Putting polypills into practice: Challenges and lessons learned. Lancet. 16 March 2017; 389: 1066–1074. DOI: 10.1016/S0140-6736(17)30558-5
- Pereira M, Araujo C, Dias P, et al. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: The EURHOBOP study. Eur J Prev Cardiol. 2014; 21: 1401–1408. DOI: 10.1177/2047487313494580
- Koopman C, Vaartjes I, Heintjes EM, et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur Heart J. 21 September 2013; 34: 3198–3205. DOI: 10.1093/eurheartj/eht368
- Zullo AR, Mogul A, Corsi K, et al. Association Between Secondary Prevention Medication Use and Outcomes in Frail Older Adults After Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 20 April 2019; 12: e004942. DOI: 10.1161/CIRCOUTCOMES.118.004942
- Mukherjee D, Fang J, Kline-Rogers E, et al. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups. Heart. 16 February 2005; 91: 381–382. DOI: 10.1136/hrt.2004.036459
- Hall M, Bebb OJ, Dondo TB, et al. Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. Eur Heart J. 12 September 2018; 39: 3798–3806. DOI: 10.1093/eurheartj/ehy517
- Hammer Y, Iakobishvili Z, Hasdai D, et al. Guideline-Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. J Am Heart Assoc. 30 October 2018; 7: e009885. DOI: 10.1161/JAHA.118.009885
- Park DW, Kim YH, Yun SC, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 14 February 2013; 34: 1662–1669. DOI: 10.1093/eurheartj/eht048
- Iqbal J, Zhang YJ, Holmes DR, et al. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: Insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up. Circulation. 8 April 2015; 131: 1269–1277. DOI: 10.1161/CIRCULATIONAHA.114.013042
DOI: https://doi.org/10.5334/gh.812 | Journal eISSN: 2211-8179
Language: English
Submitted on: Apr 23, 2020
Accepted on: Dec 1, 2021
Published on: Dec 27, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2021 Tianyu Li, Xiaofang Tang, Ying Song, Yi Yao, Xueyan Zhao, Zhan Gao, Yuejin Yang, Runlin Gao, Bo Xu, Jinqing Yuan, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.